Drug Shortage Report for TEVA-EMTRICITABINE/TENOFOVIR
| Report ID | 159201 |
| Drug Identification Number | 02399059 |
| Brand name | TEVA-EMTRICITABINE/TENOFOVIR |
| Common or Proper name | EMTRICITABINE/TENOFOVIR 200/300MG |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | TENOFOVIR DISOPROXIL FUMARATE EMTRICITABINE |
| Strength(s) | 300MG 200MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
|
Packaging sizes (GTIN)
Click here to see a list of all reports for this drug. |
(See additional packaging sizes) |
| Additional packaging sizes | 30 |
| ATC code | J05AR |
| ATC description | DIRECT ACTING ANTIVIRALS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2022-04-20 |
| Estimated end date | 2023-06-10 |
| Actual end date | 2023-06-20 |
| Shortage status | Resolved |
| Updated date | 2023-06-21 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v17 | 2022-12-01 | English | Compare |
| v16 | 2022-11-14 | French | Compare |
| v15 | 2022-11-14 | English | Compare |
| v14 | 2022-10-17 | French | Compare |
| v13 | 2022-10-17 | English | Compare |
| v12 | 2022-09-30 | French | Compare |
| v11 | 2022-09-30 | English | Compare |
| v10 | 2022-09-22 | French | Compare |
| v9 | 2022-09-22 | English | Compare |
| v8 | 2022-09-07 | French | Compare |
| v7 | 2022-09-07 | English | Compare |
| v6 | 2022-06-30 | French | Compare |
| v5 | 2022-06-30 | English | Compare |
| v4 | 2022-06-16 | French | Compare |
| v3 | 2022-06-16 | English | Compare |
| v2 | 2022-04-21 | French | Compare |
| v1 | 2022-04-21 | English | Compare |